Interferon a (IFNa) induces both apoptosis and a counteracting epidermal growth factor Erk-dependent survival response in cancer cells. In this report, IFNa increased eukaryotic elongation factor 1A (eEF-1A) protein expression by inhibition of eEF-1A degradation via a proteasome-dependent pathway. The reduction of the expression level of eEF-1A by RNA interference enhanced the apoptosis induced by IFNa on the same cells. Moreover, IFNa induced the phosphorylation of both serine and threonine in eEF-1A. These effects were paralleled by an increased co-immunoprecipitation and colocalization of eEF-1A with C-Raf. The suppression of C-Raf kinase activity with the inhibitor BAY 43-9006 completely antagonized the increase of both eEF-1A phosphorylation and expression and of C-Raf/eEF-1A colocalization induced by IFNa and enhanced apoptosis and eEF-1A ubiquitination. Cell transfection with the mutated K48R ubiquitin increased EF-1A expression and desensitized tumor cells to the modulating effects of IFNa. The dynamic simulation of 3Dstructure of eEF-1A identified putative serine and threonine phosphorylation sites. In conclusion, the interaction between eEF-1A and C-Raf increases eEF-1A stability and induces a survival activity. In the past years, much attention has been directed to the study of the genetic information and alterations that regulate eukaryotic cell proliferation and lead to neoplastic transformation. However, an increasing body of data emerges on the involvement of translational machinery in control of both cell proliferation and apoptosis.
In the past years, much attention has been directed to the study of the genetic information and alterations that regulate eukaryotic cell proliferation and lead to neoplastic transformation. However, an increasing body of data emerges on the involvement of translational machinery in control of both cell proliferation and apoptosis. [1] [2] [3] The eukaryotic translation elongation factor 1A (eEF-1A) catalyzes the first step of the protein synthesis elongation cycle. 4, 5 Two isoforms of the protein that are encoded by two different genes, eEF-1A1 and eEF-1A2 are known and they are expressed in a tissue specific manner. [6] [7] [8] [9] Besides its central role in translation, eEF-1A is involved in several cellular processes. 10, 11 Recently, it has been shown that eEF-1A1 isoform seems to play a pro-apoptotic role in erythroleukemic 11, 12 and cardiomyocyte cell lines, 13, 14 whereas eEF-1A2 isoform appears to protect from apoptosis differentiated myotubes in skeletal muscle 15 and hematopoietic cells. 16 Moreover, eEF-1A2 is an important ovarian oncogene that activates tumorigenesis and inhibits apoptosis. 17 Therefore, to perform further studies on the possible role of eEF-1A in the regulation of apoptosis in cancer cells gains interest. As experimental model we have chosen the human epidermoid lung cancer H1355 cells in which apoptosis induced by interferon a (IFNa) is well characterized. 18 Moreover, in these cells IFNa triggers an important survival mechanism mediated by an epidermal growth factor (EGF)-Ras-mitogen activated protein kinase-dependent cascade. 19 The specific inhibition of this pathway potentiates the apoptosis induced by IFNa in epidermoid cancer cell lines. [20] [21] [22] However, the mechanisms by which this signal transduction pathway antagonizes the pro-apoptotic effects of IFNa are presently unknown.
On the basis of these findings, changes of eEF-1A intracellular levels in H1355 cells exposed to IFNa were analyzed. The role of eEF-1A in the apoptosis induced by IFNa was evaluated by reducing the intracellular content of eEF-1A through small interfering RNA (siRNA). We also found that IFNa increased eEF-1A phosphorylation in both serine and threonine residues and decreased its proteasomedependent degradation. On the basis of these data and on the hyperactivation of the IFNa-induced EGF-ras-C-RafErk-dependent pathway, we have studied the molecular interaction between eEF-1A and C-Raf in H1355 cells. Moreover, it was evaluated if C-Raf could be directly responsible for post-translational modifications of eEF-1A, thus leading to its intracellular stabilization.
Results
Effect of IFNa on the expression of eEF-1A in H1355 cells. The intracellular content of eEF-1A protein and the expression of eEF-1A mRNA in H1355 cells were evaluated at different times after treatment with 2500IU/ml IFNa. The intracellular levels of eEF-1A increased about twofold after 10 min of treatment with IFNa, as evaluated by immunoblot assay, and its levels remained increased until 60 min, and returned to basal levels at 180 min (Figure 1a and b) . Northern blot analysis of total RNA extracted from H1355 cells did not show changes in eEF-1A mRNA levels, when compared to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (Figure 1c and d) . Similar results were obtained on human epidermoid head and neck cancer KB cell line (data not shown). The expression of the two isoforms of eEF-1A was also studied, and it was found that the expression of both isoforms was increased by treatment with IFNa (Figure 1e and f) . In fact, eEF-1A1 was about 0.5-fold increased after 30 min of exposure to the cytokine, whereas no change was recorded after 10 min Because the increased expression of eEF-1A appeared to be independent of changes in mRNA expression, the role of IFNa in both the ubiquitination and proteasome-dependent degradation of eEF-1A was also investigated. H1355 cells were exposed or not to 2500 IU/ml of IFNa for 5 and 60 min, in the absence or presence of the proteasome inhibitor lactacystin. At the selected times, eEF-1A was immunoprecipitated and blotted with an anti-ubiquitin antibody to evaluate ubiquitination. IFNa alone caused a significant reduction of ubiquitination detectable after 5 min of treatment, whereas IFNa in the presence of lactacystin induced an accumulation of the ubiquitinated eEF-1A (Figure 2a) . However, the treatment of H1355 with lactacystin induced an increase of eEF-1A expression that was enhanced by the concomitant treatment with IFNa ( Figure  2b and c). The accumulation of the elongation factor in the presence of lactacystin was because of the inhibition of its degradation by proteasome, as confirmed by the increase in the ubiquitinated isoform of the translation factor.
eEF-1A siRNA potentiates the apoptosis induced by IFNa. To investigate the possible role of eEF-1A in apoptosis induced by IFNa in H1355 cells, the expression level of eEF-1A was reduced by RNA interference. siRNA1 and siRNA2 were lipotransfected together or separately, and siRNA1 was the most efficient in lowering the expression level of eEF-1A. eEF-1A expression was almost reduced 80% at 72 h after transfection, whereas in cells transfected with a scramble RNA, eEF-1A expression was unaffected ( Moreover, threonine phosphorylation was maximally increased at 30 min and again reached the basal levels after 60 min, whereas serine phosphorylation augmented after 15 min of treatment with IFNa and remained high up to 180 min of exposure time (Figure 4f ). These data demonstrated that IFNa phosphorylates eEF-1A on both serine and threonine residues.
eEF-1A co-immunoprecipitates with C-Raf in H1355 cells. We have previously reported that IFNa activates an anti-apoptotic pathway mediated by an EGF-ras-C-RafMek signal transduction pathway. 19 Therefore, it was analyzed if this pathway was responsible for the phosphorylation of eEF-1A. H1355 cells, exposed or not to IFNa, were immunoprecipitated with anti-eEF-1A or anti-C-Raf antibody and blotted with anti-C-Raf or anti-eEF-1A antibody, respectively. In samples immunoprecipitated with anti-eEF-1A, a band of about 80 kDa corresponding to C-Raf was detected ( Figure 5a ) and, in samples immunoprecipitated with anti-C-Raf, a band of about 50 kDa was detected, corresponding to the molecular weight of eEF-1A (Figure 5b ). Evaluation of the ratio between C-Raf and eEF-1A band intensity demonstrated about 50% increase of C-Raf/eEF1A interaction after 20-30 min of treatment with IFNa ( Figure 5c ). These results demonstrated that the two proteins interacted with each other in basal conditions and that IFNa enhanced this interaction.
C-Raf phosphorylates eEF-1A on serine and threonine residues. To confirm that eEF-1A is a substrate of the serine-threonine kinase C-Raf, H1355 cells were treated with the C-Raf kinase inhibitor BAY 43-9006, and its effects on both phosphorylation and expression of eEF-1A were evaluated. H1355 cells were preliminarily exposed to 5 mM BAY 43-9006 for different times and the activity of the downstream target Erk was evaluated. It was found that 120 min of exposure to BAY 43-9006 induced almost complete disappearance of Erk-1/2 phosphorylation (not shown). Therefore, in all subsequent experiments, H1355 cells were pre-treated with BAY 43-9006 for 120 min and then exposed to IFNa for different times. After treatment with BAY 43-9006, both phosphothreonine and phosphoserine levels of eEF-1A were reduced (Figure 6a and b) . BAY 43-9006 completely antagonized the increase of eEF-1A expression induced by IFNa, hence caused a reduction of eEF-1A protein levels either alone or in combination with IFNa ( Figure 6c ). On the other hand, IFNa increased eEF-1A expression with a peak at 30 min as reported above (Figure 6c ). Moreover, eEF-1A was immunoprecipitated and blotted with anti-ubiquitin antibody to evaluate the ubiquitination of eEF-1A. It was found that IFNa alone decreased the ubiquitination levels of the factor after 30 and 60 min of treatment, whereas BAY 43-9006 completely antagonized this effect even inducing a clear increase of ubiquitination after 30 and 60 min of incubation of the cells with IFNa (Figure 6d ). The treatment of H1355 cells with BAY 43-9006 induced a strong reduction of Erk phosphorylation without modulating Erk expression (Figure 6e and f) . eEF-1A phosphorylation was also evaluated by an in vitro assay. In the presence of 32 P-g-ATP, recombinant C-Raf was able to phosphorylate eEF-1A immunoprecipitated with anti-eEF-1A antibody (Figure 6g) .
To exclude the involvement of other downstream kinases in the same pathway in the phosphorylation of eEF-1A, H1355 cells were exposed to the MEK-1 inhibitor U0126. Cells were pre-treated with 10 mM U0126 for 1 h and then exposed to IFNa at different times. U0126 did not induce any change in phosphothreonine and phosphoserine levels of eEF-1A (Figure 6h and i) . Moreover, U0126 decreased Erk-1/2 phosphorylation without altering Erk expression (Figure 6j and k). In addition, U0126 was not able to modify eEF-1A expression either alone or in combination with IFNa ( Figure 6l ). On the basis of these results, we have investigated whether BAY 43-9006 could antagonize the increase of eEF-1A induced by IFNa and at the same time, enhance the apoptosis caused by the cytokine in H1355 cells. After treatment with BAY 43-9006, H1355 cells were exposed or not to IFNa for 30 min or 12 h to evaluate eEF-1A expression or apoptosis (Figure 6m and n) at FACS analysis. About 29% of untreated cells overexpressed eEF-1A, whereas about 64.8% of cell population exposed to IFNa for 30 min showed . These data demonstrate that BAY 43-9006 is able to antagonize the increased phosphorylation and expression of eEF-1A induced by IFNa and that these effects are paralleled by a decrease in the ubiquitination of the translation factor and an increase in the apoptosis induced by the cytokine.
To demonstrate that IFNa modulates eEF-1A ubiquitination, we have transfected H1355 cells with the K48R ubiquitin mutant (K48R) and evaluated the expression of the translation factor before and after treatment with IFNa. The transfection with wild type (WT) ubiquitin induced an increase in the pattern of ubiquitination of intracellular proteins, whereas the transfection with K48R caused an increase in the low molecular mass isoforms and those at high molecular mass decreased, suggesting an inhibition of poly-ubiquitination (Figure 7a) . These experiments were performed at 24 h from the transfection when the maximal increase of green fluorescent cells induced by GFP was detected (Figure 7d and e). IFNa again induced an increase of eEF-1A expression in cells transfected with an irrelevant plasmid at 15 and 30 min from the beginning of the treatment (Figure 7b and c). The transfection with K48R caused per se an increase of the eEF-1A expression, which on the other hand, was slightly decreased in WT-transfected cells (Figure 7b and c) . IFNa added to K48R-transfected cells failed to increase eEF-1A expression that was already increased in untreated cells, whereas IFNa again enhanced eEF-1A expression in WTtransfected cells (Figure 7b and c) . These data suggest that IFNa is unable to affect eEF-1A protein half-life in cells in which ubiquitin mutated sites responsible for poly-ubiquitination is overexpressed.
The functional interaction between eEF-1A and C-Raf was also analyzed by confocal microscopy ( Figure 8 ). In fact, in untreated cells, the two proteins partially colocalized in the cells, and the colocalization was increased by the treatment with IFNa for 30 min (Figure 8a-c and 8d-f) . Subsequently, H1355 cells were treated with BAY 43-9006 that reduced colocalization of C-Raf with eEF-1A in untreated cells and antagonized the colocalization of the two proteins induced by IFNa (Figure 8g-i and j-l) .
Prediction of putative phosphorylated serine and threonine residues in eEF-1A. To predict the eEF-1A putative phosphorylation sites, a combined strategy involving molecular modelling and molecular dynamic simulation was used. In Figure 8m and n, the root mean square deviation (RMSD) is plotted as a function of time for the 2.0 ns simulation. After an initial rise of the RMSD to 0.2 nm, the RMSD gradually rose to 0.4 nm and after 0.5 ns remained fluctuating around this value during the simulation. Figure 8m shows the final structure of eEF-1A after dynamic simulation. By searching in PhosphoBase for Ser/Thr residues that are putative targets of phosphorylation, kinase specific motifs were recognized in the human eEF-1A protein and a score was attributed to each Ser and Thr (Supplementary Table 1 ). The recognized phosphorylation motifs were further selected on the basis of the value of two additional structural properties after 2.0 ns dynamic simulation, that is, the secondary structure and solvent accessibility. In fact, statistical analysis of protein kinase specificity determinants showed that most of the phosphorylation sites were located Table 1 ). Figure 8n shows the localization of most probable phosphorylation sites for Ser and Thr residues (Ser18, 157, 316, 383 and Thr242, 432, respectively) within the 3D model of human eEF-1A.
Discussion
In this paper we have investigated eEF-1A role in the apoptotic processes triggered by IFNa in H1355 cell line analyzing the functional and molecular interactions between eEF-1A and C-Raf. In our experimental model, IFNa induced an early upregulation of eEF-1A without increase in the levels of its transcripts. This finding suggested that the upregulation of the intracellular content of eEF-1A was post-transcriptionally modulated. Moreover, we have found that the cytokine increased both eEF-1A1 and eEF-1A2 but with a difference in degree and kinetics. In fact, eEF-1A2 was the most increased isoform and also showed a timing similar to the one recorded for total eEF-1A. These data suggested that eEF-1A2 increase was largely responsible for the upregulation of total eEF-1A. It has been reported that eEF-1A possesses a chaperone-like activity that prevents the aggregation of nascent polypeptide chains 24 and interacts with ubiquitinproteasome complex.
10 Moreover, we have described previously that IFNa modulates the ubiquitination of proteins, such as tissue transglutaminase, involved in the regulation of apoptosis in H1355 cells. 25 Therefore, it was speculated that the increase in eEF-1A protein expression could be owing to a regulatory mechanism in which the elongation factor levels are modulated through an ubiquitin-dependent pathway. In fact, IFNa decreased ubiquitinated eEF-1A and treatment of H1355 cells with the proteasome inhibitor lactacystin led to an accumulation of the ubiquitinated form of eEF-1A. This is, to our knowledge, the first report showing that IFNa increases eEF-1A expression through decrease of its ubiquitination and its possible rescue from proteasome-dependent degradation. To investigate the potential survival role of the increase in eEF-1A protein levels, the apoptotic response of the cells to IFNa was evaluated in cells in which eEF-1A was downmodulated by siRNA. In cells expressing low levels of eEF-1A, the apoptotic cell death induced by IFNa was potentiated suggesting that eEF-1A regulates the apoptosis in H1355.
Moreover, it was evaluated if eEF-1A could be found in different modified states through 2D gel electrophoresis. We found an additional spot of eEF-1A in IFNa-treated H1355 cells. The slight migration of the new protein toward an acidic pH could be caused by posttranslational phosphorylation. It was found that IFNa increased the phosphorylation of both serine and threonine residues in eEF-1A. Because in the same experimental model, IFNa induces an increase in the level and activity of epidermal growth factor receptor (EGF-R) and of the Ras-C-Raf-Mek1-Erk-1/2 signalling pathway that has a prominent role in anti-apoptotic effects, 19 it was evaluated if the phosphorylation of eEF-1A could be mediated by C-Raf. It was found that eEF-1A indeed interacts with CRaf and these effects could be potentiated by IFNa. Moreover, when the C-Raf kinase activity was blocked by Raf kinase inhibitor BAY 43-9006, a reduction in eEF-1A phosphoserine and phosphothreonine levels was found. IFNa was also able to decrease the ubiquitination of eEF-1A, and BAY 43-9006 completely blocked this effect and even induced a strong increase of the ubiquitination of the translation factor. These findings strongly support the hypothesis that the phosphorylation of eEF-1A by C-Raf is required to increase the intracellular half-life of the protein and to protect the latter from proteasome-dependent degradation. The antagonism of BAY 43-9006 on the eEF-1A overexpression induced by IFNa was also paralleled by a strong increase of apoptosis supporting the role of eEF-1A in the protection of cancer cells from the apoptosis induced by the cytokine. Therefore, these data suggest the existence of an anti-apoptotic network between translational factors, such as eEF-1A, and components of the ras-dependent signalling as C-Raf. The transfection of H1355 cells with K48R mutant ubiquitin induced per se an increase in the expression of eEF-1A that did not increase further by the treatment with IFNa. On the other hand, the overexpression of WT ubiquitin induced a slight decrease of eEF-1A that was again modulated by IFNa addition. Moreover, IFNa is unable to increase the expression of the translational factor when compared with K48R ubiquitintransfected cells. These data support the hypothesis that eEF-1A is indeed poly-ubiquitinated and that the overexpression of an ubiquitin mutant lacking the site responsible for poly-ubiquitination is alone able to increase the expression of eEF-1A. On the other hand, the overexpression of WT ubiquitin increases the poly-ubiquitination and consequent degradation of eEF-1A slightly decreasing its expression. IFNa caused again an increase in the expression of eEF-1A when compared to both non-transfected and WT ubiquitintransfected cells. These data altogether suggest that eEF-1A expression is indeed modulated via an ubiquitin-dependent pathway. We also found that U0126, a Mek-1 inhibitor, was unable to affect the changes induced by IFNa in eEF-1A phosphorylation and expression and in the colocalization of eEF-1A/C-Raf in vivo, suggesting the specific involvement of C-Raf in these changes. Finally, the in vitro kinase assay clearly showed that eEF-1A can be a substrate of C-Raf. Moreover, we used the 3D structure of EF-1A GDP from Sulfolobus solfataricus as a template for the prediction of phosphorylation putative sites. 26 To conclude, in the human epidermoid lung cancer cells, H1355, the upregulation of eEF-1A intracellular content mediated by IFNa is associated with an increase in the phosphorylation of serine and threonine residues of the protein. Our findings indicate that the effect is mediated by C-Raf, and appears to play a pro-survival function. On the basis of our previous findings, we propose that activation of CRaf by IFNa is presumably indirect and induced by upregulation of EGF-R. Moreover, for the first time, a well-known client of HSP90, C-Raf, degraded via a proteasome-dependent pathway, 27 has been demonstrated to protect eEF-1A from ubiquitin-mediated degradation. Therefore, eEF-1A is an antiapoptotic factor whose activity links the protein synthesis machinery to growth factor-elicited survival pathway and represents an important molecular target to improve strategies based on apoptosis induction.
Materials and Methods
Materials. RPMI 1640 medium and fetal bovine serum (FBS) were purchased from Cambrex. IFNa was a gift from Schering Plough (Nutley, NJ, USA). Bay 43-9006 was a gift from Bayer Pharmaceuticals Corporation, West Haven, CT, USA. Protein A-Agarose, anti-C-Raf C-12, anti-ubiquitin FL76, anti-actin I-19, antiphosphothreonine, anti-Erk, anti-pErk polyclonal antibodies, rabbit anti-mouse and goat anti-rabbit immunoglobulin conjugated to horseradish peroxidase were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phosphoserine PSR-45 monoclonal antibody (mAb) and lactacystin were from Sigma (Milan, Italy). AntieEF-1A CB-KK1 mAb was purchased from Upstate (Charlottesville, VA, USA). Irrelevant mouse IgG1 was purchased form DAKO (Bastrup, Denmark). Recombinant Raf-1 was purchased from GloboZymes (Carlsbad, CA, USA).
U0126 was from Promega (Madison, WI, USA). Other primary antibodies used were HT7 for eEF1A-1/EF-1a, CB5 for eEF1A-2/S1. 28 The construction of both plasmids pDG268, the WT vector in which expression of a linear fusion of His6-tagged human ubiquitin and enhanced GFP is driven by the human UBC promoter, and pDG279, containing the K48R mutant version of ubiquitin, has been described elsewhere. 29 Cell culture. The human lung epidermoid carcinoma H1355 cell line, obtained from American Type Tissue Collection (Rockville, MD, USA), was grown in RPMI 1640 medium supplemented with heat inactivated FBS, 100 U/ml penicillin, 100 mg/ ml streptomycin, 1% L-glutamine at 371C in a 5% CO 2 atmosphere. For RNA hybridization, Western blot analysis and apoptosis evaluation, the cells were treated with 2500 IU/ml IFNa.
Northern blot analysis. Cytoplasmic RNA was extracted from cells using Trizol reagent (Gibco BRL). RNA (2 mg) was resolved on formaldehyde agarose gel, transferred to nylon membrane and hybridized to 32 P-labeled EF-1A cDNA (clone pAN7) or 32 P-labeled GAPDH cDNA 30 probes as described by Maniatis et al.
31
Cytosolic extracts and Western blot analysis. H1355 cells were scraped, washed twice in cold phosphate-buffered saline (PBS) and resuspended in 20-40 ml of lysis buffer (50 mM Tris-HCl pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mg/ml aprotinin, leupeptin, pepstatin, 1 mM Na 3 VO 4 , 1 mM NaF) for 30 min on ice and centrifuged at 14 000 Â g for 20 min at 41C. Protein concentration was determined by a modified Bradford method, using the Bio-Rad protein assay and compared with BSA standard curve. Cytosolic proteins (2 mg) were separated by SDS-PAGE, electrotransferred to nitrocellulose and reacted with the different antibody. Blots were then developed using enhanced chemiluminescence detection reagents (SuperSignal West Pico, Pierce) and exposed to X-ray film. All films were scanned by using Adobe photoshop software.
Two-dimensional gel electrophoresis. H1355 cells were homogenized in 20 mM Tris-HCl pH 7.8 containing 1 mg/ml aprotinin, leupeptin and pepstatin. Cell extract (150-300 mg) was diluted in 125 ml of rehydration solution and applied to IPG Strip 7 cm, pH 3-10, for 12 h by using the rehydration loading method (Amersham). Proteins were then focused for up to 15 000 Vh at a maximum voltage of 5000 V. After the first dimension, the strip was placed in equilibration solution (6 M urea, 2% SDS, 30% glycerol, 50 mM Tris-HCl pH 8.8) containing 1% DTT for 10 min and then in the same buffer containing 2.5% iodacetamide for 5 min. After equilibration, strip was loaded on 12% SDS-PAGE for the second dimension. Proteins were detected by Western blotting.
Immunoprecipitation. Total protein extracts (500 mg) were subjected to immunoprecipitation with 2 mg of anti-eEF-1A, or 2 mg of anti-C-Raf for 16 h at 41C. Immune complexes were collected with 20 ml of protein A-agarose for 2 h at 41C. The protein A-agarose/immune complex was washed four times with cold PBS, resuspended in 30 ml of SDS-loading buffer, heated to 951C for 5 min and used for Western blot analysis using anti-C-Raf, anti-eEF-1A, anti-phosphoserine, antiphosphothreonine and anti-ubiquitin.
SiRNA. SiRNAs were designed according to MWG Biotech software and synthesized by Dharmacom Research Inc. The sense sequences were: siRNA1, 5 0 -AUG CGG UGG CAU CGA CAA AdTdT; siRNA2, 5 0 -AAG CAG UGG ACA AGA AGG CdTdT. The RNA oligonucleotides were used according to manufacturer's protocol. RNA scramble ready to use was also purchased from Dharmacom.
Cell transfection. Cells (150 000/well) were seeded into six-well plates 24 h before transfection in RPMI1640 antibiotics free (2 ml) and then transfected with 100 nM siRNA by using Lipofectamine 2000 (LF2000) according to the manufacturer's instructions (Invitrogen). After 24, 48 and 72 h of incubation, the cells were used for Western blot analysis. Cytofluorimetric analysis was performed by using 30 000 cells/well. After 72 h from transfection, the medium was replaced, and the cells were exposed to 2500 IU/ml IFNa for 48 h. Cells were then collected for FACS analysis.
Analysis of annexin V binding. Labelling of apoptotic cells was performed using an Annexin-V kit as described by the manufacturer (MedSystem Diagnostic). Analysis of apoptotic cells was performed by flow cytometry (FACScan, Becton FACS Analysis of eEF-1A expression. For EF-1A detection, cells were fixed with 3% paraformaldehide in PBS solution for 30 min at RT and permeabilized with 0.5% Tween 20 in PBS for 5 min. For the detection of EF-1A, the cells were exposed to anti-EF-1A mAb (1 : 1000) for 30 min at 41C and subsequently exposed to phycoerythrin-conjugated anti-mouse goat antiserum (1 : 500) for 30 min at 41C. After final washes, cells were examined by FACScan flow cytometer (FACScan, Becton Dickinson). For each sample, 2 Â 10 4 events were acquired. Analysis was carried out by triplicate determination on at least three separate experiments.
Immunofluorescence detection of eEF-1A and C-Raf. H1355 cancer cells were seeded into 35 mm culture dishes on sterile coverslips and allowed to attach for 24 h. Subsequently, the cells were incubated for 10 min in the presence of IFNa as described above. The medium was then removed, cells were washed with PBS and fixed with 1 ml Cytofix/cytoperm (Pharmigen) for 45 min at 411C. Subsequently, the fixation buffer was removed, and cells were washed with 1 ml of washing buffer. For visualization of eEF-1A and C-Raf, the cells were exposed to anti-eEF-1A mAb and anti-C-Raf rabbit antiserum for 10 min at 411C and washed with washing buffer. Subsequently, the cells were exposed to both rhodamineconjugated anti-mouse rabbit antiserum and FITC-conjugated anti-rabbit goat antiserum for 10 min at 411C. After final washes, coverslips were mounted on the dishes using a 50% solution of glycerol in PBS. The cells were examined with the help of LEICA TCS SP2 confocal microscope.
Kinase assay. H1355 cell extracts were immunoprecipitated with anti-eEF-1A mAb as reported above. The immunocomplexes were then incubated at 301C for 60 min in 30 ml of 1 Â kinase buffer (25 mM glycerol-phosphate, 50 mM Tris-HCl pH 7.5, 2 mM DTT, 10 mM MgCl 2 , 25 mM cold ATP) in the presence of recombinant Raf-1 kinase and 5 mCi of 32 P-g-ATP (Amersham). The reaction was stopped by the addition of 10 ml loading buffer and separated by SDS-PAGE.
Computational methods.
To obtain a 3D model of human eEF-1A, the eEF-1A protein sequence 32 (Swiss-Prot entry P68104) (http://swissmodel.expasy.org) was used as target 33 and the crystallographic structure of archaeal EF-1A in complex with GDP from S. solfataricus was used as template 34 (pdb entry: 1JNK). 35 Atomic coordinates obtained from the SWISS-MODEL server were then used for molecular dynamic simulation at 300 K. To improve the accuracy of the model, a 2 ns molecular dynamic simulation by GROMACS 3.2 package was performed using GROMACS software package 3.2 (www.gromacs.org) and with the GROMOS96 force-hfield. Water was modelled by simple point-charge (SPC) model. 36 The protein model was solvated with water molecules in a periodic cubic box of 10.5 nm. The SHAKE algorithm was used to constrain all bond lengths. 37 The Berendsen algorithm was used for the temperature control 38 , and the long-range electrostatic interactions were treated with the particle-mesh Ewald method. 39 The atomic coordinates for the final structure of eEF-1A model were stored in a pdb format file obtained by averaging the atomic positions relative to the last 1.0 ns of the trajectory. The RMSD of all protein atoms with respect to the crystal structure was calculated after least-squares fitting of atom positions to the crystal structure and, subsequently, averaged over all atoms.
Serine and threonine phosphorylation consensus sites in human eEF-1A were searched at the NetPhos 2.0 server (http://www.cbs.dtu.dk/databases/PhosphoBase/ ), on the basis of phosphorylation sequences collection data. 23 The secondary structure and solvent accessibility data were extracted from the eEF-1A model after dynamic simulation by running appropriate scripts in DeepViewer SPDBV software. 40 Statistical analysis. All data are expressed as mean7S.D. Statistical analysis was performed by analysis of variance (ANOVA) with Neumann-Keul's multiple comparison or Kolmogorov-Smirnov test where appropriate.
